Cargando…
Biologics, Pharmacovigilance, and Patient Safety: It’s All in the Name
The most appropriate naming convention for biologics and biosimilars has been an area of significant debate. The ultimate decision will have an impact on patient safety, pharmacovigilance program effectiveness, and, potentially, the overall adoption of biosimilars in the United States. This article...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398272/ https://www.ncbi.nlm.nih.gov/pubmed/27459655 http://dx.doi.org/10.18553/jmcp.2016.22.8.927 |